Cortisol profiles differentiated in adolescents and young adult males with fragile X syndrome versus autism spectrum disorder

Sara M. Matherly, Jessica Klusek, Angela J. Thurman, Andrea Mcduffie, Leonard J Abbeduto, Jane E. Roberts

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Fragile X syndrome (FXS) and non-syndromic autism spectrum disorder (ASD) are distinct disorders with overlapping behavioral features. Both disorders are also highly associated with anxiety with abnormal physiological regulation implied mechanistically. Some reports suggest atypical hypothalamus-pituitary-adrenal (HPA) axis function, indexed via aberrant cortisol reactivity, in both FXS and non-syndromic ASD. However, no study has compared cortisol reactivity across these two disorders, or its relationship to ASD symptom severity. Methods: Cortisol reactivity (prior to and following a day of assessments) was measured in 54 adolescent/young adult males with FXS contrasted to 15 males with non-syndromic ASD who had low cognitive abilities. Results: Greater ASD symptom severity was related to increased cortisol reactivity and higher levels at the end of the day, but only in the non-syndromic ASD group. Elevated anxiety was associated with increased HPA activation in the group with FXS alone. Conclusions: Taken together, findings suggest a unique neuroendocrine profile that distinguishes adolescent/young adult males with FXS from those with non-syndromic ASD. Severity of ASD symptoms appears to be related to cortisol reactivity in the non-syndromic ASD sample, but not in FXS; while anxiety symptoms are associated with HPA activation in the FXS sample, but not in ASD despite a high prevalence of ASD, anxiety and physiological dysregulation characteristic in both populations.

Original languageEnglish (US)
JournalDevelopmental Psychobiology
DOIs
StateAccepted/In press - Jan 1 2017

Fingerprint

Fragile X Syndrome
Hydrocortisone
Young Adult
Anxiety
Hypothalamus
Autism Spectrum Disorder
Aptitude

Keywords

  • Anxiety
  • ASD
  • FXS
  • HPA Axis

ASJC Scopus subject areas

  • Developmental and Educational Psychology
  • Developmental Neuroscience
  • Developmental Biology
  • Behavioral Neuroscience

Cite this

Cortisol profiles differentiated in adolescents and young adult males with fragile X syndrome versus autism spectrum disorder. / Matherly, Sara M.; Klusek, Jessica; Thurman, Angela J.; Mcduffie, Andrea; Abbeduto, Leonard J; Roberts, Jane E.

In: Developmental Psychobiology, 01.01.2017.

Research output: Contribution to journalArticle

@article{bbb52a5c1d4748928ffaa8cb5f9ef3d5,
title = "Cortisol profiles differentiated in adolescents and young adult males with fragile X syndrome versus autism spectrum disorder",
abstract = "Background: Fragile X syndrome (FXS) and non-syndromic autism spectrum disorder (ASD) are distinct disorders with overlapping behavioral features. Both disorders are also highly associated with anxiety with abnormal physiological regulation implied mechanistically. Some reports suggest atypical hypothalamus-pituitary-adrenal (HPA) axis function, indexed via aberrant cortisol reactivity, in both FXS and non-syndromic ASD. However, no study has compared cortisol reactivity across these two disorders, or its relationship to ASD symptom severity. Methods: Cortisol reactivity (prior to and following a day of assessments) was measured in 54 adolescent/young adult males with FXS contrasted to 15 males with non-syndromic ASD who had low cognitive abilities. Results: Greater ASD symptom severity was related to increased cortisol reactivity and higher levels at the end of the day, but only in the non-syndromic ASD group. Elevated anxiety was associated with increased HPA activation in the group with FXS alone. Conclusions: Taken together, findings suggest a unique neuroendocrine profile that distinguishes adolescent/young adult males with FXS from those with non-syndromic ASD. Severity of ASD symptoms appears to be related to cortisol reactivity in the non-syndromic ASD sample, but not in FXS; while anxiety symptoms are associated with HPA activation in the FXS sample, but not in ASD despite a high prevalence of ASD, anxiety and physiological dysregulation characteristic in both populations.",
keywords = "Anxiety, ASD, FXS, HPA Axis",
author = "Matherly, {Sara M.} and Jessica Klusek and Thurman, {Angela J.} and Andrea Mcduffie and Abbeduto, {Leonard J} and Roberts, {Jane E.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1002/dev.21578",
language = "English (US)",
journal = "Developmental Psychobiology",
issn = "0012-1630",
publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - Cortisol profiles differentiated in adolescents and young adult males with fragile X syndrome versus autism spectrum disorder

AU - Matherly, Sara M.

AU - Klusek, Jessica

AU - Thurman, Angela J.

AU - Mcduffie, Andrea

AU - Abbeduto, Leonard J

AU - Roberts, Jane E.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background: Fragile X syndrome (FXS) and non-syndromic autism spectrum disorder (ASD) are distinct disorders with overlapping behavioral features. Both disorders are also highly associated with anxiety with abnormal physiological regulation implied mechanistically. Some reports suggest atypical hypothalamus-pituitary-adrenal (HPA) axis function, indexed via aberrant cortisol reactivity, in both FXS and non-syndromic ASD. However, no study has compared cortisol reactivity across these two disorders, or its relationship to ASD symptom severity. Methods: Cortisol reactivity (prior to and following a day of assessments) was measured in 54 adolescent/young adult males with FXS contrasted to 15 males with non-syndromic ASD who had low cognitive abilities. Results: Greater ASD symptom severity was related to increased cortisol reactivity and higher levels at the end of the day, but only in the non-syndromic ASD group. Elevated anxiety was associated with increased HPA activation in the group with FXS alone. Conclusions: Taken together, findings suggest a unique neuroendocrine profile that distinguishes adolescent/young adult males with FXS from those with non-syndromic ASD. Severity of ASD symptoms appears to be related to cortisol reactivity in the non-syndromic ASD sample, but not in FXS; while anxiety symptoms are associated with HPA activation in the FXS sample, but not in ASD despite a high prevalence of ASD, anxiety and physiological dysregulation characteristic in both populations.

AB - Background: Fragile X syndrome (FXS) and non-syndromic autism spectrum disorder (ASD) are distinct disorders with overlapping behavioral features. Both disorders are also highly associated with anxiety with abnormal physiological regulation implied mechanistically. Some reports suggest atypical hypothalamus-pituitary-adrenal (HPA) axis function, indexed via aberrant cortisol reactivity, in both FXS and non-syndromic ASD. However, no study has compared cortisol reactivity across these two disorders, or its relationship to ASD symptom severity. Methods: Cortisol reactivity (prior to and following a day of assessments) was measured in 54 adolescent/young adult males with FXS contrasted to 15 males with non-syndromic ASD who had low cognitive abilities. Results: Greater ASD symptom severity was related to increased cortisol reactivity and higher levels at the end of the day, but only in the non-syndromic ASD group. Elevated anxiety was associated with increased HPA activation in the group with FXS alone. Conclusions: Taken together, findings suggest a unique neuroendocrine profile that distinguishes adolescent/young adult males with FXS from those with non-syndromic ASD. Severity of ASD symptoms appears to be related to cortisol reactivity in the non-syndromic ASD sample, but not in FXS; while anxiety symptoms are associated with HPA activation in the FXS sample, but not in ASD despite a high prevalence of ASD, anxiety and physiological dysregulation characteristic in both populations.

KW - Anxiety

KW - ASD

KW - FXS

KW - HPA Axis

UR - http://www.scopus.com/inward/record.url?scp=85034966916&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034966916&partnerID=8YFLogxK

U2 - 10.1002/dev.21578

DO - 10.1002/dev.21578

M3 - Article

C2 - 29171019

AN - SCOPUS:85034966916

JO - Developmental Psychobiology

JF - Developmental Psychobiology

SN - 0012-1630

ER -